A Clinical Review on HMG-CoA Reductase Inhibitors (Statins)-induced Hyperglycemia and New-onset Diabetes Mellitus (NODM)
1. 请及时下载文件确认是否正确, 系统将在 2026-08-18 15:47:30 删除文件
2. 如若文件有误请驳回应助文件, 求助状态即回到求助中
3. 如若文件正确请及时点击确认, 若超过时后系统自动默认为已完结
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
NMP Maideen, ARH Jumale, AK Albasti…
Cardiovascular & …, 2026
benthamdirect.com
Introduction Due to their potent lipid-lowering capabilities, 3-hydroxy-3-methylglutyryl-coenzyme A (HMG-CoA) reductase inhibitors, commonly referred to as statins, are widely utilized for the primary and secondary prevention of cardiovascular disease. However, there is growing evidence that statin use may be associated with an increased risk of hyperglycemia and new-onset diabetes mellitus (NODM). This narrative review aims to summarize current understanding of statin-induced NODM by examining clinical data …
